<PubmedArticle>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">27489863</PMID>
<DateCompleted>
<Year>2016</Year>
<Month>08</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection">
<Journal>
<ISSN IssnType="Print">2331-4737</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>3</Volume>
<Issue>5-6</Issue>
<PubDate>
<Year>2016</Year>
</PubDate>
</JournalIssue>
<Title>Oncoscience</Title>
<ISOAbbreviation>Oncoscience</ISOAbbreviation>
</Journal>
<ArticleTitle>Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.</ArticleTitle>
<Pagination>
<MedlinePgn>164-72</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.18632/oncoscience.307</ELocationID>
<Abstract>
<AbstractText>There is limited data on co-expression of FGFR/FGR amplifications and PI3K/ AKT/mTOR alterations in breast cancer. Tumors from patients with metastatic breast cancer referred to our Phase I Program were analyzed by next generation sequencing (NGS). Genomic libraries were selected for all exons of 236 (or 182) cancer-related genes sequenced to average depth of &gt;500× in a CLIA laboratory (Foundation Medicine, Cambridge, MA, USA) and analyzed for all classes of genomic alterations. We report genomic profiles of 112 patients with metastatic breast cancer, median age 55 years (range, 27-78). Twenty-four patients (21%) had at least one amplified FGFR or FGF. Fifteen of the 24 patients (63%) also had an alteration in the PI3K/ AKT/mTOR pathway. There was no association between alterations in FGFR/FGF and PI3K/AKT/mTOR (P=0.49). Patients with simultaneous amplification in FGFR/FGF signaling and the PI3K/AKT/mTOR pathway had a higher rate of SD≥6 months/PR/ CR when treated with therapies targeting the PI3K/AKT/mTOR pathway than patients with only alterations in the PI3K/AKT/mTOR pathway (73% vs. 34%; P=0.0376) and remained on treatment longer (6.8 vs. 3.7 months; P=0.053). Higher response rates were seen in patients with simultaneous amplification in FGFR/FGF signaling and alterations in the PI3K/AKT/mTOR pathway who were treated with inhibitors of that pathway. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wheler</LastName>
<ForeName>Jennifer J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo>
<Affiliation>Translational clinical oncology, Novartis Pharmaceuticals, Cambridge, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Atkins</LastName>
<ForeName>Johnique T</ForeName>
<Initials>JT</Initials>
<AffiliationInfo>
<Affiliation>Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Janku</LastName>
<ForeName>Filip</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Moulder</LastName>
<ForeName>Stacy L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo>
<Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stephens</LastName>
<ForeName>Philip J</ForeName>
<Initials>PJ</Initials>
<AffiliationInfo>
<Affiliation>Foundation Medicine, Cambridge, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yelensky</LastName>
<ForeName>Roman</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Foundation Medicine, Cambridge, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Valero</LastName>
<ForeName>Vicente</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miller</LastName>
<ForeName>Vincent</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Foundation Medicine, Cambridge, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kurzrock</LastName>
<ForeName>Razelle</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>The Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, La Jolla, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Meric-Bernstam</LastName>
<ForeName>Funda</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 CA016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2016</Year>
<Month>06</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Oncoscience</MedlineTA>
<NlmUniqueID>101636666</NlmUniqueID>
<ISSNLinking>2331-4737</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">FGFR</Keyword>
<Keyword MajorTopicYN="N">PI3K</Keyword>
<Keyword MajorTopicYN="N">breast cancer</Keyword>
<Keyword MajorTopicYN="N">next-generation sequencing</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2016</Year>
<Month>03</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2016</Year>
<Month>05</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2016</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">27489863</ArticleId>
<ArticleId IdType="doi">10.18632/oncoscience.307</ArticleId>
<ArticleId IdType="pii">307</ArticleId>
<ArticleId IdType="pmc">PMC4965259</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10655437</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Pharmacol Sci. 2009 Dec;30(12):624-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19836845</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Anticancer Drugs. 2014 Feb;25(2):183-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24100276</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Breast Cancer Res. 2007;9(2):R23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17397528</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20952405</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer Ther. 2014 May;13(5):1382-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24608573</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1998 Jan 15;58(2):352-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9443417</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15863030</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Rep. 2014 Jan 30;6(2):377-87</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24440717</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2008 Aug 1;68(15):6084-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18676830</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2009 Apr 30;28(17):1892-903</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19330026</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Cancer. 2010 Feb;10(2):116-29</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20094046</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2014 Mar;25(3):552-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24265351</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2010 Apr 8;29(14):2013-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20101236</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2012 Oct 4;490(7418):61-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23000897</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2012 Mar 10;30(8):777-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22271473</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2010 Mar 1;70(5):2085-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20179196</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2010 May 15;70(10):4151-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20460524</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocr Relat Cancer. 2012 Jun 18;19(4):R115-29</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22508544</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Feb 15;8(4):580-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19182515</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>